Technical Analysis for XLRN - Acceleron Pharma Inc.

Grade Last Price % Change Price Change
grade C 44.16 -6.18% -2.91
XLRN closed down 6.18 percent on Friday, March 22, 2019, on 63 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical XLRN trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 200 DMA Bearish 0.00%
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 MACD Bearish Signal Line Cross Bearish 0.00%
Mar 22 Bollinger Band Squeeze Range Contraction 0.00%
Mar 22 Outside Day Range Expansion 0.00%
Mar 21 20 DMA Support Bullish -6.18%
Mar 21 Crossed Above 200 DMA Bullish -6.18%
Mar 21 Bollinger Band Squeeze Range Contraction -6.18%
Mar 21 BB Squeeze Started Range Contraction -6.18%
Mar 20 20 DMA Support Bullish -2.37%

Older signals for XLRN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. The company develops sotatercept and ACE-536 that are in Phase II clinical trials to treat anemia and associated complications in patients with ß-thalassemia and myelodysplastic syndromes (MDS), and red blood cell disorders; and dalantercept, which is in Phase II clinical trials to inhibit blood vessel formation in tumors through the vascular endothelial growth factor pathway inhibitors. It has collaboration, license, and option agreement with Celgene Corporation. The company, formerly known as Phoenix Pharma, Inc., was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Biotechnology Cancer Life Sciences Rare Diseases Tumors Anemia Celgene Myelodysplastic Syndrome Myelodysplastic Syndromes Therapeutics For Cancer Ace 536
Is XLRN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 59.59
52 Week Low 32.53
Average Volume 530,982
200-Day Moving Average 46.7792
50-Day Moving Average 43.752
20-Day Moving Average 45.4885
10-Day Moving Average 46.169
Average True Range 1.9293
ADX 10.86
+DI 18.3619
-DI 17.949
Chandelier Exit (Long, 3 ATRs ) 42.1921
Chandelier Exit (Short, 3 ATRs ) 47.1779
Upper Bollinger Band 48.0222
Lower Bollinger Band 42.9548
Percent B (%b) 0.24
BandWidth 11.139958
MACD Line 0.6228
MACD Signal Line 0.7328
MACD Histogram -0.11
Fundamentals Value
Market Cap 1.7 Billion
Num Shares 38.6 Million
EPS -2.49
Price-to-Earnings (P/E) Ratio -17.73
Price-to-Sales 108.28
Price-to-Book 7.53
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 49.07
Resistance 3 (R3) 49.59 48.48 48.25
Resistance 2 (R2) 48.48 47.23 48.22 47.97
Resistance 1 (R1) 46.32 46.46 45.77 45.80 47.70
Pivot Point 45.21 45.21 44.93 44.95 45.21
Support 1 (S1) 43.05 43.96 42.50 42.53 40.62
Support 2 (S2) 41.94 43.19 41.68 40.35
Support 3 (S3) 39.78 41.94 40.07
Support 4 (S4) 39.26